Journal of stem cell research & therapy最新文献

{"title":"CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric Neuroblastoma","authors":"Zhi-yong Zhong, Bao-jun Shi, Hui Zhou, Wen Wang","doi":"10.4172/2157-7633.1000394","DOIUrl":"https://doi.org/10.4172/2157-7633.1000394","url":null,"abstract":"Objectives: Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN gene exists in nearly half of the NB patient and its association with rapid disease progression and poor outcome is controversial. Cancer Stem Cells (CSCs) characterization in NB has been rarely studied. This study is to figure out whether the MYCN gene and CSCs are associated with chemotherapy resistance and survival time in the NB patients. \u0000Methods: Based on unequivocal pathological diagnosis, 50 NB patients are recruited. MYSN amplification is measured before any therapy. The CSCs are derived and their multi-potencies are tested by directed differentiation. Response to chemotherapy and average survival time of these patients are gathered and compared with following groups: CD133+, CD133-, MYCN ≥ 5, MYCN<5, CD133+ plus MYCN ≥ 5, CD133- plus MYCN<5. \u0000Results: CD133+ CSCs differentiate into neuron like cells; CD133+ patients have significant poorer response to chemotherapy comparing with the CD133- patients (P<0.01); CD133+ and MYCN ≥ 5 patients have significantly shorter average survival time than the CD133- and MYCN<5 patients (P<0.01). \u0000Conclusions: CD133+ CSCs produce chemo-resistance. CD133 and MYCN amplification can be used together as a prognostic value for predicting disease outcome.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2157-7633.1000394","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45172946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metadicholî and Red Cell Distribution Width (RDW) in CKD patients","authors":"R. Pr","doi":"10.4172/2157-7633.1000392","DOIUrl":"https://doi.org/10.4172/2157-7633.1000392","url":null,"abstract":"Red blood cells originate in the bone marrow. Red cell distribution width (RDW) show sizes of circulating erythrocytes (RBC) and has been explored in several large clinical databases to be a robust marker of adverse clinical outcomes in patients. The prognostic value of RDW is seen in other conditions with end-organ dysfunction such as renal failure or. Elevated RDW levels are of significance in diseases such as kidney diseases. The high RDW levels are an indication of increased oxidative stress and closely related to the presence and poor prognosis of the disease. \u0000No known therapy exists that can normalize RDW levels. In this paper, we present here case studies using Metadichol® [1] that leads to normal RDW levels in patients with CKD and PKD.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2157-7633.1000392","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41474715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secretome of Mesenchymal Stem Cells Grown in Hypoxia Accelerates Wound Healing and Vessel Formation In Vitro","authors":"Sushma Bartaula-Brevik","doi":"10.23937/2469-570X/1410045","DOIUrl":"https://doi.org/10.23937/2469-570X/1410045","url":null,"abstract":"Hypoxia is one of the factors that trigger the release of inflammatory and vasculogenic cytokines during tissue regeneration. Mesenchymal stem cells (MSC) with and without endothelial cells (EC) were cultured in vitro in normoxic and hypoxic environments. The mRNA expression of inflammatory and vasculogenic cytokines were evaluated at 1, 12, 24 and 48 hours. After 48 hours of incubation in normoxic and hypoxic conditions, supernatants termed as conditioned medium (CM) from each group were collected and analyzed. The protein level of VEGF-A in the CM was determined by ELISA. The effects of the CM from different groups on EC were evaluated using wound healingand tube formation assays. The mRNA expression of IL-1β, IL-6 and IL-8 was up-regulated in both the normoxic and hypoxic co-culture (MSC/EC) group, compared with the mono-culture normoxic group. The VEGF-A protein level was higher in the hypoxic monoand co-culture group. Wound closure was accelerated by CM from the monoand co-culture hypoxic groups compared with both normoxic groups. Measurements of tube formation were higher in the hypoxic mono-culture group compared with the normoxic group. The conditioned medium obtained from hypoxia preconditioning of the cells accelerated wound healing and vessel formation in vitro.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42564396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Umbilical Cord Blood Stem Cells and Chitosan Hydrogels Produce Similar Beneficial Effects in Acute Myocardial Infarctions and Ischemic Cardiomyopathies","authors":"R. Henning","doi":"10.23937/2469-570X/1410047","DOIUrl":"https://doi.org/10.23937/2469-570X/1410047","url":null,"abstract":"","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42735420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase Ib Open Clinical Trial to Assess the Safety of AutologousMesenchymal Stem Cells for the Treatment of NonrevascularizableCritical Lower Limb Ischemia","authors":"Riera del Moral L, Salazar Alvarez A, Stefanov Kiuri S, Tong H, Riera de Cubas L, Garcia Olmo D, Garcia Arranz M","doi":"10.4172/2157-7633.1000391","DOIUrl":"https://doi.org/10.4172/2157-7633.1000391","url":null,"abstract":"Background: Critical limb ischemia is a highly disabling disease, characterized by chronic pain at rest, ulceration and tissue tropism attributable to arterial occlusion. Despite significant advances in recent years in treating this disease, there are patients who, for technical reasons or because of the benefit/risk balance, have no therapeutic options other than amputation of the affected limb. \u0000Objective: This study’s objective was to assess the feasibility and safety of autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AT-MSC) implantation in patients with lower limb ischemia who are not candidates for surgical or endovascular revascularization. \u0000Methods: This is a pragmatic, phase Ib, open, one-arm clinical trial, with a 1-year follow-up after cell implantation. The dose was 1 × 106 AT-MSCs/kg. AT-MSCs were diluted into a final volume of 25 mL of Ringer solution and injected as 25 aliquots of 1 mL into each injection site on the limb. Injection sites were selected below the knee at 25 different sites of the ischemic calf muscle along the tibial and peroneal arteries. Liposuction was done in the abdomen. \u0000Results: A total of 7 patients underwent treatment for 21 months. Two patients showed no serious complications with the liposuction, only pain and mild infection. No serious cell implantation-related adverse event occurred during the follow-up, although 2 patients had to undergo amputation. The ankle-brachial index and clinical assessment of the limb improved during the follow-up. \u0000Conclusion: In conclusion, AT-MSC treatment of critical limb ischemia is feasible, safe and has promising initial results for salvaging limbs in the short term.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42737815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing clinical guidelines to treat neurological and neurosurgical disorders with stem cells","authors":"F. Ruiz-Navarro, G. Kobinia","doi":"10.4172/2157-7633-C1-026","DOIUrl":"https://doi.org/10.4172/2157-7633-C1-026","url":null,"abstract":"","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43356048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopoietic Stem Cell Transplantation: The Quality Matters","authors":"K. Haider","doi":"10.4172/2157-7633.1000390","DOIUrl":"https://doi.org/10.4172/2157-7633.1000390","url":null,"abstract":"List of Abbreviations: EGP: Epidermal Growth Factor; FBS: Fetal Bovine Serum; FGF-2: Fibroblast Growth Factor-2; HGF-1: Hepatocyte Growth Factor-1; HSCs: Hematopoietic Stem Cells; IGF-1: Insulin-like Growth Factor; IL: Interleukin; MSCs: Mesenchymal Stem Cells; PBSCs: Peripheral Blood Stem Cells; PDGF: Platelet Derived Growth Factor; PRP: Platelet Rich Plasma; TGF-β: Transforming Growth Factor-β; VEGF: Vascular Endothelial Growth Factor","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43035822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Possible Ameliorative Effect of Mesenchymal Stem Cells and Curcumin Onbleomycin Induced Lung Injuries in the Adult Male Rats: Histological and Immunohistochemical Study","authors":"Zeinab MAltaib, Aisha EMansy, Abeer M ElMahlawy, D. Sabry","doi":"10.4172/2157-7633.1000389","DOIUrl":"https://doi.org/10.4172/2157-7633.1000389","url":null,"abstract":"Background: Bleomycin (BLM) is a chemotherapeutic agent that produces pulmonary fibrosis. Curcumin is a naturally occurring compound, uses in medicine and has many beneficial therapeutic effects. Bone Marrow Mesenchymal Stem Cells (BMSCs) is a novel approach with great therapeutic potential for the treatment of fatal pulmonary fibrosis. Aim of the work: To evaluate whether or not curcumin improves the stem cells therapeutic effects on bleomycin induced lung injuries in adult male rats. Material and methods: Fifty adult male rats were included and divided equally into 5 groups. Group I (control), Group II (bleomycin group): The rats received single intratracheal instillation of 1 mg/kg of bleomycin, Group III (curcumin group): The rats received curcumin 200 mg/kg body weight orally by gastric tube 5 days/week for 4 weeks, Group IV (stem cell group): The rats injected intraperitoneal by a single dose 3 × 106 of MSCs after 4 weeks of bleomycin injection, Group V (stem cell and curcumin group): The rats received curcumin as in the groups III after 4 weeks of bleomycin injection for 4 weeks and injected with the MSCs intraperitoneal after the last dose of curcumin. Lung samples were processed and examined using histological and immunohistochemical techniques. Results: Group II showed thickening of interalveolar septa by RBCs and mononuclear cellular infiltration. Many collapsed alveoli, while other alveoli were dilated and ruptured. Their bronchiole lined by epithelial cells with deeply stained nuclei and their lumen were full of exfoliated epithelial cells. A significant increase in collagen and elastic fibers accumulation, positive PCNA immunoreactivity within the nuclei of cells lining alveoli and marked positive COX2 immunoreactivity within cytoplasmic of alveolar epithelial cells and in the bronchiolar epithelium. Group III, IV showed attenuation of some histological changes as compared to group II, while Group V showed improvement of the histological and immunohistochemical changes described before. Conclusion: Bone marrow derived mesenchymal can attenuate bleomycin induced lung injuries in rats, but curcumin can yield better beneficial effect over the BMSCs therapy alone.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 1","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2017-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43839020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach forProstate Cancer Therapy","authors":"Firdous H Beigh, N. Syeed, M. Maqbool, Rita Singh Majumdhar","doi":"10.4172/2157-7633.1000388","DOIUrl":"https://doi.org/10.4172/2157-7633.1000388","url":null,"abstract":"Prostate cancer (CaP) is considered as a vexing challenge for clinical management because of its resistance to the conventional therapies, resulting in most deaths from this disease. The current treatment options including castration shows minimal effect, as most of the patients develop resistance and relapse of more aggressive Castration Resistant Prostate Cancer (CRPC). BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), an oncogenic member of the polycomb group gene family and a transcriptional repressor has emerged as a key regulator in numerous processes including proliferation, differentiation, senescence, and stem cell renewal. Accumulating evidences have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in most human malignancies, including Prostate cancer. Therefore, in this review, we provide the significant evidences suggesting the potential of BMI1 as a therapeutic target in the management of prostate cancer.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":" ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48949824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyplexinol: A Natural BMP Complex with Osteoinductive and Anti- Inflammatory Activity Promotes De Novo Bone and Joint Tissue Growth","authors":"James J. Scaffidi, K. Vieira","doi":"10.4172/2157-7633.1000387","DOIUrl":"https://doi.org/10.4172/2157-7633.1000387","url":null,"abstract":"Sustaining the health of the bones and joints is a pertinent issue that is challenging for the medical community nationwide. Chronic inflammation has been implicated as a major contributing factor for the systemic degradation and disruption of the articular and skeletal systems. Accordingly, medical practitioners and pharmaceutical companies are currently directing treatments toward restoring healthy inflammatory response in order to strengthen the human body’s capability to target endogenous degradation of bone and joint tissue. However, improving overall health involves more than targeting inflammation, and should also focus on activating cellular machinery which supports the regeneration of de novo bone and cartilage through a process known as osteoinduction. Bone Morphogenetic Proteins (BMPs) have been identified as the regulators of the osteogenic differentiation of Mesenchymal Stem Cells (MSCs) into multiple cell lineages such as osteoblasts and chondrocytes. Cyplexinol® is a natural BMP complex, which consists of a collagen fragment matrix with the BMPs and endogenous growth factors bound within and to the matrix. Upon oral administration of the BMP-complex, the BMP moieties bind to receptors within the GI lumen where they quickly confer both osteoinductive and anti-inflammatory activity. It is the osteogenic properties of the BMPs which differentiate the MSCs into osteoblasts to promote the growth of de novo bone tissue, providing the critical surface for minerals to bind to healthy bones. Similarly, the osteoinductive proteins have also been proven to turn MSCs into chondrocytes for new cartilage tissue growth via proteoglycan excretion. This review will describe clinical work which demonstrates the efficacy of Cyplexinol®, highlighting how this supplement induces MSC differentiation.","PeriodicalId":89694,"journal":{"name":"Journal of stem cell research & therapy","volume":"7 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}